
UBS downgraded Schott Pharma (STTPF) to Neutral from Buy with a EUR 22.30 price target The firm cites weaker syringe demand for the downgrade. Published first on TheFly – the
Compare up to 40 stocks
Compared Stocks: 1 / 40

UBS downgraded Schott Pharma (STTPF) to Neutral from Buy with a EUR 22.30 price target The firm cites weaker syringe demand for the downgrade. Published first on TheFly – the

RBC Capital analyst Charles Weston downgraded Schott Pharma (STTPF) to Sector Perform from Outperform with a price target of EUR 25, up from EUR 21. The firm cites valuation for

BofA upgraded Schott Pharma (STTPF) to Neutral from Underperform with a EUR 27 price target The firm sees the company meeting its medium term organic revenue growth target. Published first

Deutsche Bank downgraded Schott Pharma (STTPF) to Hold from Buy with a EUR 25 price target The firm cites valuation for the downgrade following the stock’s recent rally. Published first

JPMorgan initiated coverage of Schott Pharma (STTPF) with an Overweight rating and EUR 27.10 price target The firm says Schott is one of the few medical technology names where risk

Barclays analyst Jonathon Unwin upgraded Schott Pharma (STTPF) to Overweight from Equal Weight with a price target of EUR 27, up from EUR 16. The firm sees the company’s growth

Barclays upgraded Schott Pharma (STTPF) to Overweight from Equal Weight with a price target of EUR 27, up from EUR 16. The firm sees the company’s growth accelerating to high

Citi raised the firm’s price target on Schott Pharma (STTPF) to EUR 27 from EUR 21 and keeps a Buy rating on the shares. Published first on TheFly – the

RBC Capital upgraded Schott Pharma (STTPF) to Outperform from Sector Perform with a price target of EUR 21, up from EUR 18. Preliminary Q3 figures show CER revenue growth of

Deutsche Bank upgraded Schott Pharma (STTPF) to Buy from Hold with a price target of EUR 22, up from EUR 16. Following a slow first half caused by reduced demand
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Dec 10, 2026Before Open | $3.73B | ― | ― | ― | ― |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.